Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial — Meletios A Dimopoulos (2022) | RDL Network
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial
EPd demonstrated a statistically significant improvement in OS versus Pd in patients with RRMM previously treated with lenalidomide and a PI who had disease refractory to last therapy. In this setting, ELOQUENT-3 is the first randomized study of a triplet regimen incorporating a monoclonal antibody and Pd to improve both PFS and OS significantly.
Meletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, Philippe Moreau, Naoki Takezako, Mitsuo Hori, Xavier Leleu, Richard LeBlanc, Kazuyuki Suzuki, Marc‐Steffen Raab, Paul G. Richardson, Mihaela Popa McKiver, Ying‐Ming Jou, Suresh G. Shelat, Michael Robbins, B. Rafferty, Jesús F. San Miguel
Meletios A Dimopoulos, Sagar Lonial, Darrell White, Philippe Moreau, Katja Weisel, Jesús F. San Miguel, Ofer Shpilberg, Sebastian Grosicki, Ivan Špıčka, Adam Walter‐Croneck, Hila Magen, María‐Victoria Mateos, Andrew R. Belch, Donna Reece, Meral Beksaç, Andrew Spencer, Heather Oakervee, Robert Z. Orlowski, Masafumi Taniwaki, Christoph Röllig, Hermann Einsele, Morio Matsumoto, ,
Katja Weisel, Meletios A Dimopoulos, Jesús F. San Miguel, Agne Paner, Monika Engelhardt, Fiona Taylor, Jennifer Lord‐Bessen, Christine Yip, Mike Greenwood, Jackson Tang, Michèle Cavo
Paul G. Richardson, Aurore Perrot, Jesús F. San Miguel, Meral Beksaç, Ivan Špıčka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A Dimopoulos, Shang‐Yi Huang, Jiří Minařík, Michèle Cavo, H. Miles Prince, Sandrine Macé, Rick Zhang, Franck Dubin, Mony Chenda Morisse, Kenneth C. Anderson
Katja Weisel, Meletios A Dimopoulos, Jesús F. San Miguel, Agne Paner, Monika Engelhardt, Fiona Taylor, Jennifer Lord‐Bessen, David Yao, Christine Yip, Mike Greenwood, Jackson Tang, Michèle Cavo
Discussion(0)
No comments yet. Be the first to comment.